Research progress of the resistance mechanism and reversal strategies of ALK inhibitors in NSCLC

ZHANG Di; RAN Dongzhi; YU Yu; GAN Zongjie

doi:10.11665/j.issn.1000-5048.20200603

Journal of China Pharmaceutical University > 2020 > 51(6): 655-663. > DOI: 10.11665/j.issn.1000-5048.20200603

ZHANG Di, RAN Dongzhi, YU Yu, GAN Zongjie. Research progress of the resistance mechanism and reversal strategies of ALK inhibitors in NSCLC[J]. Journal of China Pharmaceutical University, 2020, 51(6): 655-663. DOI: 10.11665/j.issn.1000-5048.20200603

Citation:

PDF (1570 KB)

Research progress of the resistance mechanism and reversal strategies of ALK inhibitors in NSCLC

Funds: This study was supported by the National Natural Science Foundation of China (No.21907013) and the Scientific and Technological Research Program of Chongqing Municipal Education Commission (No.KJQN201900431)

More Information

Received Date: February 24, 2020
Revised Date: October 21, 2020

Graphical Abstract

Abstract

Abstract

Anaplastic lymphoma kinase (ALK) inhibitors are regarded as effective drugs for the treatment of ALK-positive NSCLC. However,the emergence of drug resistance has limited its further clinical application. This article briefly introduces the resistance mechanism of ALK inhibitors including acquired secondary mutations,gene amplification,bypass signaling pathway activation and reviews the recent advances on the reversal strategies such as drug combination,developing novel PROTACs to overcome drug resistance,so as to provide some reference for the development of ALK inhibitors.
- NSCLC,
- ALK inhibitors,
- drug resistance,
- reversal strategies,
- advances

FullText(HTML)

References (51)

References

[1]	.Science，1994，263（5151）：1281?1284.
[2]	Chiarle R，Voena C，Ambrogio C，et al.The anaplastic lymphoma kinase in the pathogenesis of cancer［J］.Nat Rev Cancer，2008，8（1）：11?23.
[3]	Sasaki T，Rodig SJ，Chirieac LR，et al.The biology and treatment of EML4-ALK non-small cell lung cancer［J］.Eur J Cancer，2010，46（10）：1773?1780.
[4]	Soda M，Choi YL，Enomoto M，et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer［J］.Nature，2007，448（7153）：561?566.
[5]	Golding B，Luu A，Jones R，et al.The function and therapeutic targeting of anaplastic lymphoma kinase （ALK） in non-small cell lung cancer （NSCLC）［J］.Mol Cancer，2018，17（1）：1?15.
[6]	Roskoski R.Anaplastic lymphoma kinase （ALK） inhibitors in the treatment of ALK-driven lung cancers［J］.Pharmacol Res，2017，117：343?356.
[7]	Kwak EL，Bang YJ，Camidge DR，et al.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer［J］.N Engl J Med，2010，363（18）：1693?1703.
[8]	Casaluce F，Sgambato A，Sacco PC，et al.Resistance to crizotinib in advanced non-small cell lung cancer （NSCLC） with ALK rearrangement：mechanisms，treatment strategies and new targeted therapies［J］.Curr Clin Pharmacol，2016，11（2）：77?87.
[9]	Gainor J，Dardaei L，Yoda S，et al.Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer［J］.Cancer Discov，2016，6（10）：1118?1133.
[10]	Shaw AT，Friboulet L，Leshchiner I，et al.Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F［J］.N Engl J Med，2016，374（1）：54?61.
[11]	Yarden Y，Elkabets M.Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways［M］.Cham：Springer International Publishing，2018.
[12]	Lin JJ，Riely GJ，Shaw AT.Targeting ALK：precision medicine takes on drug resistance［J］.Cancer Discov，2017，7（2）：137?155.
[13]	Kong X，Pan P，Sun H，et al.Drug discovery targeting anaplastic lymphoma kinase （ALK）［J］.J Med Chem，2019，62（24）：10927?10954.
[14]	Lin JJ，Shaw AT.Resisting resistance：targeted therapies in lung cancer［J］.Trends Cancer，2016，2（7）：350?364.
[15]	Doebele RC，Pilling AB，Aisner DL，et al.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer［J］.Clin Cancer Res，2012，18（5）：1472?1482.
[16]	Katayama R，Shaw AT，Khan TM，et al.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers［J］.Sci Transl Med，2012，4（120）：120ra17.
[17]	Ou SHI，Azada M，Hsiang DJ，et al.Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib （CH5424802/RO5424802） in ALK-rearranged NSCLC patients who progressed on crizotinib［J］.J Thorac Oncol，2014，9（4）：549?553.
[18]	Jamme P，Descarpentries C，Gervais R，et al.Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice［J］.Clin Lung Cancer，2019，20（4）：297?304.
[19]	Yamaguchi N，Lucena-Araujo AR，Nakayama S，et al.Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer［J］.Lung Cancer，2014，83（1）：37?43.
[20]	Kim HR，Kim WS，Choi YJ，et al.Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation［J］.Mol Oncol，2013，7（6）：1093?1102 .
[21]	Katayama R，Sakashita T，Yanagitani N，et al.P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer［J］.EBioMedicine，2016，3：54?66.
[22]	Nijenhuis CM，Haanen JB，Schellens JH，et al.Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma［J］？Cancer Treat Rev，2013，39（4）：305?312.
[23]	Shi JY，Bai Y，Peng KW，et al.Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance［J］.J China Pharm Univ（中国药科大大学学报），2019，50（5）：523?530.
[24]	Chen Z，Sasaki T，Tan X，et al.Inhibition of ALK，PI₃K/MEK，and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene［J］.Cancer Res，2010，70（23）：9827?9836.
[25]	Sang J，Acquaviva J，Friedland JC，et al.Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer［J］.Cancer Discov，2013，3（4）：430?443.
[26]	Jhaveri K，Ochiana SO，Dunphy MP，et al.Heat shock protein 90 inhibitors in the treatment of cancer：current status and future directions［J］.Expert Opin Investig Drugs，2014，23（5）：611?628.
[27]	Yun MR，Lim SM，Kim SK，et al.Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors［J］.Cancer Res，2018，78（12）：3350?3362.
[28]	Fukuda K，Takeuchi S，Katayama R，et al.HDAC inhibition overcomes crizotinib-resistance by mesenchymal-epithelial transition （MET） in EML4-ALK lung cancer cells［J］.J Thorac Oncol，2017，12（1）：S382?S383.
[29]	Shen J，Najafi S，St?ble S，et al.A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment［J］.Cell Death Differ，2018，25（12）：2053?2070.
[30]	Asghar U，Witkiewicz AK，Turner NC，et al.The history and future of targeting cyclin-dependent kinases in cancer therapy［J］.Nat Rev Drug Discov，2015，14（2）：130?146.
[31]	Wood AC，Krytska K，Ryles HT，et al.Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma［J］.Clin Cancer Res，2017，23（11）：2856?2868.
[32]	Isozaki H，Ichihara E，Takigawa N，et al.Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases［J］.Cancer Res，2016，76（6）：1506?1516.
[33]	Sasaki T，Koivunen J，Ogino A，et al.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors［J］.Cancer Res，2011，71（18）：6051?6060.
[34]	Koh J，Jang JY，Keam B，et al.EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor （HIF）-1α and STAT3［J］.Oncoimmunology，2016，5（3）：e1108514.
[35]	Bylicki O，Paleiron N，Margery J，et al.Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer［J］.Target Oncol，2017，12（5）：563?569.
[36]	Felip E，de Braud FG，Maur M，et al.Ceritinib plus nivolumab （NIVO） in patients （pts） with anaplastic lymphoma kinase positive （ALK⁺） advanced non-small cell lung cancer （NSCLC）［J］.J Clin Oncol，2017，35（15_suppl）：2502.
[37]	Drilon A，Ou SI，Cho BC，et al.Repotrectinib （TPX-0005） is a next-generation ROS₁/TRK/ALK inhibitor that potently inhibits ROS₁/TRK/ALK solvent-front mutations［J］.Cancer Discov，2018，8（10）：1227?1236.
[38]	Cui JJ，Zhai D，Deng W，et al.TPX-0005，a novel ALK/ROS₁/TRK inhibitor，effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R，ROS1 G2032R and TRKA G595R mutants［J］.Eur J Cancer，2016，69：S32.
[39]	Zhai DY，Deng W，Huang J，et al.Abstract 3161：TPX-0005，an ALK/ROS₁/TRK inhibitor，overcomes multiple resistance mechanisms by targeting SRC/FAK signaling［C］.Cancer Res，2017，77（13_suppl）：3161.
[40]	Xu M.Predicting inactive conformations of protein kinases （蛋白激酶非活性构象的预测方法研究）［D］.Shanghai：Fudan University，2019.
[41]	Blanc J，Geney R，Menet C.Type II kinase inhibitors：an opportunity in cancer for rational design［J］.Anti-Cancer Agents Med Chem，2013，13（5）：731?747.
[42]	Pan P，Yu H，Liu Q，et al.Combating drug-resistant mutants of anaplastic lymphoma kinase with potent and selective type-I1/2 inhibitors by stabilizing unique DFG-shifted loop conformation［J］.ACS Cent Sci，2017，3（11）：1208?1220.
[43]	Zhao Z，Wu H，Wang L，et al.Exploration of type II binding mode：a privileged approach for kinase inhibitor focused drug discovery［J］.ACS Chem Biol，2014，9（6）：1230?1241.
[44]	Tu CH，Lin WH，Peng YH，et al.Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase （ALK）［J］.J Med Chem，2016，59（8）：3906?3919.
[45]	Mathi GR，Kang CH，Lee HK，et al.Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R［J］.Eur J Med Chem，2017，126：536?549.
[46]	Geng K，Xia Z，Ji Y，et al.Discovery of 2，4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation［J］.Eur J Med Chem，2018，144：386?397.
[47]	Chen YF，Wu JX，Wang AL，et al.Discovery of N-（5-（（5-chloro-4-（（2-（isopropylsulfonyl）phenyl）amino）pyrimidin-2-yl）amino）-4-methoxy-2-（4-methyl-1，4-diazepan-1-yl）phenyl）acrylamide （CHMFL-ALK/EGFR-050） as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC［J］.Eur J Med Chem，2017，139：674?697.
[48]	Ott GR，Cheng M，Learn KS，et al.Discovery of clinical candidate CEP-37440，a selective inhibitor of focal adhesion kinase （FAK） and anaplastic lymphoma kinase （ALK）［J］.J Med Chem，2016，59（16）：7478?7496.
[49]	Sun X，Rao Y.PROTACs as potential therapeutic agents for cancer drug resistance［J］.Biochemistry，2020，59（3）：240?249.
[50]	Zhang C，Han X，Yang X，et al.Proteolysis targeting chimeras （PROTACs） of anaplastic lymphoma kinase （ALK）［J］.Eur J Med Chem，2018，151：304?314.
[51]	Kang CH，Lee DH，Lee CO，et al.Induced protein degradation of anaplastic lymphoma kinase （ALK） by proteolysis targeting chimera （PROTAC）［J］.Biochem Biophys Res Commun，2018，505（2）：542?547.

Cited By

Cited by

Periodical cited type(3)

1.	李锦华，祁萍，乔慧. ALK-TKI耐药后获得性RET融合晚期非小细胞肺癌1例报道并文献复习. 肿瘤防治研究. 2024(08): 703-706 .
2.	王瑞峰，赵相欣，孙印，秦桥花，赵冬梅. 降解FAK的PROTAC分子的设计合成及生物活性研究. 中国药物化学杂志. 2023(07): 481-489 .
3.	王梓灵，郭瑜婕，朱芸芸，陈乐，吴婷，刘大会，黄必胜，杜鸿志. 金花茶有效部位抑制表皮生长因子受体(EGFR)抗非小细胞肺癌的作用机制研究. 中国中药杂志. 2021(20): 5362-5371 .

Other cited types(2)

Get Citation

PDF

XML

Article views (404) PDF downloads (1113) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Research progress of the resistance mechanism and reversal strategies of ALK inhibitors in NSCLC

Abstract

References

Cited by

Periodical cited type(3)

Other cited types(2)

Catalog

Export File

Citation

Format

Content